{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:8854"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:8854","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Diagnostic delay in plasma cell dyscrasias","abstract":"Background: Multiple myeloma is associated with significant diagnostic delay, and early mortality, particularly after emergency presentation. Given the varied symptoms of myeloma, symptom-based strategies to improve diagnosis may be ineffective - alternative strategies are needed. Methods: 1) Symptoms and diagnostic pathway were assessed in patients with myeloma. Analysis considered those with and without prior knowledge of monoclonal gammopathy of undetermined significance (MGUS). 2) Blood test results prior to diagnosis were assessed in a cohort of myeloma patients. 3) Patients presenting acutely to hospital with medical complaints were recruited to assess the prevalence of detectable paraproteinemia. Results: 1) Those diagnosed via acute services had more end organ damage and more advanced disease without a longer diagnostic pathway, suggesting faster disease progression. Prior knowledge of MGUS was associated with less end organ damage. 2) Change in blood test results was demonstrated in the two years before diagnosis 3) There was a higher prevalence of paraproteinemia in acute hospital admissions compared to expected population rates (5.3% vs 3.2%) Discussion: Multiple factors affect the diagnostic pathway, including aggressiveness of disease. Feasible strategies to improve diagnosis could be developed, including automated processes to test based on routine blood test results, and identification of MGUS, for instance in acute medical admissions.","abstract_html":"Background: Multiple myeloma is associated with significant diagnostic delay, and early mortality, particularly after emergency presentation. Given the varied symptoms of myeloma, symptom-based strategies to improve diagnosis may be ineffective - alternative strategies are needed. Methods: 1) Symptoms and diagnostic pathway were assessed in patients with myeloma. Analysis considered those with and without prior knowledge of monoclonal gammopathy of undetermined significance (MGUS). 2) Blood test results prior to diagnosis were assessed in a cohort of myeloma patients. 3) Patients presenting acutely to hospital with medical complaints were recruited to assess the prevalence of detectable paraproteinemia. Results: 1) Those diagnosed via acute services had more end organ damage and more advanced disease without a longer diagnostic pathway, suggesting faster disease progression. Prior knowledge of MGUS was associated with less end organ damage. 2) Change in blood test results was demonstrated in the two years before diagnosis 3) There was a higher prevalence of paraproteinemia in acute hospital admissions compared to expected population rates (5.3% vs 3.2%) Discussion: Multiple factors affect the diagnostic pathway, including aggressiveness of disease. Feasible strategies to improve diagnosis could be developed, including automated processes to test based on routine blood test results, and identification of MGUS, for instance in acute medical admissions.","abstract_has_math":false,"creators":["Atkin, Catherine Emma"],"institution":"University of Birmingham","degree_name":"d_m_d","degree_level":"d_m_d","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2019,"date_issued":"2019-07","date_published":"2019-07","updated_at":"2026-11-19T09:30:24Z","subjects":["RC Internal medicine","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/8854/7/Atkin2019MD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A8854","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["na"]},{"key":"dc:creator","label":"Author","values":["Atkin, Catherine Emma"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2019-07-17"]},{"key":"dc:date.issued","label":"Date","values":["2019-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/8854/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_m_d"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_m_d"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["RC Internal medicine","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/8854/7/Atkin2019MD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Background: Multiple myeloma is associated with significant diagnostic delay, and early mortality, particularly after emergency presentation. Given the varied symptoms of myeloma, symptom-based strategies to improve diagnosis may be ineffective - alternative strategies are needed. Methods: 1) Symptoms and diagnostic pathway were assessed in patients with myeloma. Analysis considered those with and without prior knowledge of monoclonal gammopathy of undetermined significance (MGUS). 2) Blood test results prior to diagnosis were assessed in a cohort of myeloma patients. 3) Patients presenting acutely to hospital with medical complaints were recruited to assess the prevalence of detectable paraproteinemia. Results: 1) Those diagnosed via acute services had more end organ damage and more advanced disease without a longer diagnostic pathway, suggesting faster disease progression. Prior knowledge of MGUS was associated with less end organ damage. 2) Change in blood test results was demonstrated in the two years before diagnosis 3) There was a higher prevalence of paraproteinemia in acute hospital admissions compared to expected population rates (5.3% vs 3.2%) Discussion: Multiple factors affect the diagnostic pathway, including aggressiveness of disease. Feasible strategies to improve diagnosis could be developed, including automated processes to test based on routine blood test results, and identification of MGUS, for instance in acute medical admissions."]},{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Diagnostic delay in plasma cell dyscrasias"]}]}],"canonical_facts":{"dc:contributor.sponsor":["na"],"dc:creator":["Atkin, Catherine Emma"],"dc:date":["2019-07-17"],"dc:date.issued":["2019-07"],"dc:description.abstract":["Background: Multiple myeloma is associated with significant diagnostic delay, and early mortality, particularly after emergency presentation. Given the varied symptoms of myeloma, symptom-based strategies to improve diagnosis may be ineffective - alternative strategies are needed. Methods: 1) Symptoms and diagnostic pathway were assessed in patients with myeloma. Analysis considered those with and without prior knowledge of monoclonal gammopathy of undetermined significance (MGUS). 2) Blood test results prior to diagnosis were assessed in a cohort of myeloma patients. 3) Patients presenting acutely to hospital with medical complaints were recruited to assess the prevalence of detectable paraproteinemia. Results: 1) Those diagnosed via acute services had more end organ damage and more advanced disease without a longer diagnostic pathway, suggesting faster disease progression. Prior knowledge of MGUS was associated with less end organ damage. 2) Change in blood test results was demonstrated in the two years before diagnosis 3) There was a higher prevalence of paraproteinemia in acute hospital admissions compared to expected population rates (5.3% vs 3.2%) Discussion: Multiple factors affect the diagnostic pathway, including aggressiveness of disease. Feasible strategies to improve diagnosis could be developed, including automated processes to test based on routine blood test results, and identification of MGUS, for instance in acute medical admissions."],"dc:format":["text"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/8854/7/Atkin2019MD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/8854/"],"dc:subject":["RC Internal medicine","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"dcterms:accessrights":["public"],"dc:title":["Diagnostic delay in plasma cell dyscrasias"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_m_d"],"dc:type.qualificationname":["d_m_d"]},"updated_at":"2026-11-19T09:30:24Z"}